Thursday 16 October, 2025
Introduction: Elranatamab (ELRA) is a heterodimeric humanized bispecific antibody approved for treatment of patients with relapsed/refractory multiple myeloma (RRMM). ELRA…
Read moreAbstracts
Step-Wise Population Pharmacokinetic Modeling Approach to Characterize Complex Absorption of Lenacapavir Following SC Administration in Healthy Participants
Thursday 16 October, 2025
Introduction: Lenacapavir (LEN) is a novel long-acting, first-in-class, selective inhibitor of HIV-1 capsid function, currently approved for multidrug resistant HIV-1…
Read moreTowards an Inflammation Simulation Model: Development and Validation of a Mathematical Model of the Human Inflammatory Response to Acute and Prolonged Lipopolysaccharide Exposure
Thursday 16 October, 2025
Introduction: Cytokines are inflammatory mediators that play a pivotal role in the initiation and orchestration of the immune response [1]. IL-6,…
Read moreDevelopment of QSP platform model for predicting clinical efficacy and CRS incidence of CD3 bispecifics in STEAP1 Prostate Cancer
Thursday 16 October, 2025
Introduction: CD3 bispecifics are engineered antibodies that bind CD3 on T cells and target antigens on cancer cells (TAAs), activating…
Read moreIntegrating PKPD and Agent-Based Modeling to Explore Tuberculosis Relapse after Treatment.
Thursday 16 October, 2025
Introductions: The immune system’s significance in Tuberculosis (TB) drug development is often underestimated due to experimental complexities. In this study,…
Read moreStudy design optimization in paediatric rare diseases: a case study on empagliflozin in paediatric heart failure
Thursday 16 October, 2025
Objectives: Paediatric heart failure is rare (1-8/100’000), but it represents a relevant health burden. Current therapy is unsatisfactory, with 5-year…
Read moreA Neural Networks-assisted NLME Framework: Case Study on Modeling Platelet Counts
Thursday 16 October, 2025
Objectives: Thrombocytopenia, a frequent adverse event type in cancer therapy, requires clinical platelet management to avoid high-grade thrombocytopenia and to…
Read moreDose rationale for bedaquiline in paediatric patients with multi drug-resistant tuberculosis
Thursday 16 October, 2025
Objectives: At the forefront of the causes of death globally, multi-drug resistant (MDR) tuberculosis (TB) manifests severely in children, posing…
Read moreEtravirine’s Pharmacokinetics Explored: PBPK Modeling and DDI Analysis with Efavirenz for Cancer Treatment
Thursday 16 October, 2025
Objectives: Drug repurposing is an emerging strategy in the quest for new cancer therapies, offering distinct advantages such as leveraging…
Read moreAdvancing Quantitative Systems Pharmacology (QSP) Disease Progression Modeling with Real-World Data: Applications for Patients with Unintentional Weight Loss
Thursday 16 October, 2025
Background: Unintentional weight loss is a symptom of serious disease or illness. Two widely recognized, yet, under diagnosed diseases that…
Read more